News – Bryologyx

Press Releases

BryoLogyx Announces Additions to Board of Directors and Scientific and Medical Advisory Board

December 21, 2021

BryoLogyx Appoints Oncology Leaders, Drs. Richard Schilsky and Justin Stebbing, to Scientific and Medical Advisory Board

MAY 26, 2021

BryoLogyx presents poster entitled “Bryostatin-1 enhances cancer immunotherapy efficacy by increasing tumor antigen density and activating T-cells” at the New York Academy of Sciences annual conference Frontiers in Cancer Immunotherapy 2021 held virtually

MAY 12, 2021

BryoLogyx Announces Completion of World’s First GMP Synthesis of Bryostatin-1

OCTOBER 13, 2020

BryoLogyx Announces Cooperative Research and Development Agreement for Bryostatin-1 With National Cancer Institute

AUGUST 04, 2020

BRIEF-Neurotrope Announces Strategic Partnership With BryoLogyx

JUNE 10, 2020

Bryologyx Names David Crockford Vice President of Clinical Development and Logistics

FEBRUARY 3, 2020

BryoLogyx Announces Expanded Exclusive Bryostatin Patent License

AUGUST 1, 2019

BryoLogyx Names Omar Duramad, Ph.D., as Chief Scientific Officer

JULY 30, 2019

William Grossman, M.D., Ph.D., Named to BryoLogyx Board of Directors

MAY 28, 2019

BryoLogyx Acquires Rights for Bryostatin and Analogues, for Development as Possible Treatment for Cancer And HIV

DECEMBER 10, 2018

Bryologyx In The News

Neurotrope secures supply of Bryostatin-1

JUNE 10, 2020

BryoLogyx takes on HIV, cancer-developed synbio compound – San Francisco Business Times – bizjournals.com

DECEMBER 11, 2018

The synthetic sibling of an expensive molecule harvested from a tiny seaweed-dwelling animal could lead to next-generation cancer drugs or a functional cure for HIV, an East Bay company believes.